Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

MedicalJane

JUNE 29, 2018

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. Prior to this week, the U.S. “It’s fantastic.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

AUGUST 21, 2019

The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Puff Puff Post

JANUARY 1, 2020

Cancer patients suffer not only from cancer, but the damaging effects of treatment. Doctors prescribe various forms of opiods to cancer patients for pain. At other times cannabis treats the pain of cancer patients better. Early studies suggest, and patients confirm, the use of cannabis i n pain management for cancer.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

Cannabis Law Report

NOVEMBER 25, 2021

Epilepsy Treatment. This study is, of course, well-vetted, and has offered plenty of hope to sufferers of epilepsy. The use of CBD seems to ease the number of seizures patients have considerably, which has caused many medical professionals to take notice and begin prescribing it to others. Ease Opioid Addiction.

CBD 52

CBD Clinical Trials Epilepsy Chronic Pain 52

Cannabis Law Report

NOVEMBER 16, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “For

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Puff Puff Post

JANUARY 1, 2020

Cancer patients suffer not only from cancer, but the damaging effects of treatment. Doctors prescribe various forms of opiods to cancer patients for pain. At other times cannabis treats the pain of cancer patients better. Early studies suggest, and patients confirm, the use of cannabis i n pain management for cancer.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Cannabis Law Report

JANUARY 5, 2022

This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., therapies, MYMD-1 has been shown in these pre-clinical studies to selectively block TNF-? Unlike other anti-TNF-?

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

The Joint Blog

FEBRUARY 24, 2021

This is not the first medicinal trial of its kind. Cannabis and CBD oils have often been used to reduce the effects of epilepsy and several other neurological issues, so why not Parkinson’s? Though trialing is relatively new and there is no clear scientific evidence as of yet, anecdotal evidence from patients is looking positive.

Treatment 55

Treatment Clinical Trials Collective Patients 55

The Joint Blog

APRIL 22, 2022

Treats Epilepsy. Furthermore, the FDA recognizes the benefits of CBD oil and has approved many branded oils to treat some forms of epilepsy. When patients are given CBD oil, it may decrease their seizures’ frequency. But, if it is consumed along with the right amount of therapy, it might work wonders for PTSD patients.

Oil 26

Oil CBD Topical Clinical Trials 26

Greencamp

AUGUST 16, 2018

Because of the very rapid progression of ALS in the majority of patients, understanding how cannabis could help in the alleviation of symptoms is incredibly important for ALS sufferers. Both upper and lower motor neurons suffer severe damage in ALS patients. As few as 10% of ALS patients live longer than 10 years after being diagnosed.

Strains 94

Strains Cannabinoids Research and Development Indica 94

CannaMD

AUGUST 8, 2020

Designed to treat seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome , Epidiolex is a purified (> 98% oil-based) CBD extract administered via oral spray. Prior to receiving FDA approval, Epidiolex underwent a number of clinical trials establishing the medical efficacy of CBD.

CBD 99

CBD DEA Research and Development Hemp 99

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 52

Epilepsy Clinical Trials Research and Development Pharmaceutical 52

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Third-party clinical studies investigating oral psilocybin have reported compelling anti-depressant effects.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

SEPTEMBER 20, 2021

Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. VRP324 uses a preassembled device and cartridge to propel the CBD powder formulation into the nose to the brain via the olfactory nerve/bulb.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.

Research and Development 52

Research and Development Medicine Access Media 52

Green Relief

MAY 13, 2018

A 2014 study found that traumatic brain injury ( TBI ) patients who tested positive for THC were more likely to survive with less impairment than TBI patients who abstained from marijuana. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

THC 64

THC CBD Cannabinoids Research and Development 64

Cannabis Law Report

DECEMBER 21, 2019

Autism is a very serious health condition that affects patients’ communication and social interaction skills thus making the development and maintenance of a social relationship very difficult. Reports gathered show that the behavioral patterns patients show are more repetitive than erratic. A closer look at CBD And Autism.

Research and Development 59

Research and Development CBD Conditions Therapy 59

Green Relief

MAY 12, 2018

A 2014 study found that traumatic brain injury ( TBI ) patients who tested positive for THC were more likely to survive with less impairment than TBI patients who abstained from marijuana. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Puff Puff Post

DECEMBER 28, 2018

We go deep into what this might mean for the future of therapy for Autism Spectrum Disorders (ASD), and how we might see the use of CBD oil for autism. A sample of 120 patients aged between 5 and 29 years old with mild to severe autism are currently being given two different cannabis oil formulas or placebo. What Exactly is Autism ?

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

DECEMBER 30, 2019

Since 2014, annual appropriations bills have been amended to include a spending restriction to prevent the Department of Justice from enforcing the federal prohibition of marijuana against state-legal medical cannabis programs, businesses, and patients. Included in the final FY 2020 spending package). It took immediate effect upon passage.

Legislation 59

Legislation Patients Access Banking 59